SecBot SecBot
Biotech Drug Report Generated Nov 7, 2026

VIR-5525

VIR·Vir Biotechnology, Inc.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Phase 1
Time to market
VIR-5525 is in Phase 1 dose escalation with no efficacy data yet. If successful through Phase 1, Phase 2 and potentially registrational trials would follow, meaning commercial launch is likely 5+ years away under typical timelines.
Why 2/10
VIR-5525 is an early Phase 1 asset still in dose escalation with no scheduled binary catalyst (PDUFA, pivotal readout, or AdComm) in the next ~12 months. The next potential catalyst would be initial Phase 1 safety/efficacy data at a future medical conference, but management has not guided to a specific date. The drug is one of three TCE programs at Vir and is not the company's lead value driver.
Actionable Insight NEUTRAL

VIR-5525 is still in Phase 1 dose escalation with no efficacy data or binary catalyst on the calendar. The next meaningful event would be initial safety/efficacy data at a future scientific conference, but management has not guided to a specific timeline. Vir's near-term stock-moving catalysts are elsewhere: the ECLIPSE Phase 3 hepatitis delta topline (Q4 2026) and VIR-5500's progression toward pivotal trials. VIR-5525 is a watch-and-wait program for now.

Price Chart

Loading chart...

Executive Summary

VIR-5525 is an investigational EGFR-targeting dual-masked T-cell engager (TCE) being developed by Vir Biotechnology (Nasdaq: VIR) for solid tumors. It is in a Phase 1 first-in-human clinical trial (NCT06960395) as monotherapy and in combination with pembrolizumab across multiple EGFR-expressing tumor types including non-small cell lung cancer, colorectal cancer, and head and neck cancers. First patient was dosed in July 2025, and as of the Q3 2026 earnings update (November 4, 2026), the drug continues to progress through dose escalation with no efficacy data reported yet. VIR-5525 is Vir's third TCE program to enter the clinic, following VIR-5500 (PSMA, partnered with Astellas) and VIR-5818 (HER2). At this early stage with no near-term binary catalyst, VIR-5525 is a minor driver of Vir's investment thesis relative to the company's more advanced hepatitis delta and oncology programs.

How It Works

VIR-5525 is a dual-masked T-cell engager (TCE), a type of immunotherapy that works like a molecular bridge. One end grabs onto EGFR proteins on the surface of cancer cells, and the other end grabs onto CD3 proteins on immune T-cells, forcing the T-cells to attack the cancer. The 'dual-masked' design uses PRO-XTEN technology to keep the drug inactive until it reaches the tumor environment, where enzymes in the tumor remove the mask. This is intended to reduce side effects (like cytokine release syndrome) by preventing the drug from activating T-cells in healthy tissue.

Trial Status

Phase 1 first-in-human trial (NCT06960395) is actively recruiting. The study has four parts: Part 1 (monotherapy dose escalation) and Part 2 (combination with pembrolizumab dose escalation) are ongoing. As of the Q3 2026 earnings call (November 4, 2026), VIR-5525 continues to progress through dose escalation in both monotherapy and combination therapy across lung cancer, colorectal cancer, head and neck squamous cell carcinoma, and cutaneous squamous cell carcinoma. No efficacy data or dose-expansion results have been reported. The trial plans to enroll approximately 450 participants.

The Two-Sided Case

▲ Bull Case5
Uses the same PRO-XTEN dual-masked TCE platform as VIR-5500, which received FDA Fast Track designation and a global Astellas collaboration, providing platform validation.
Targets EGFR, a well-validated oncology target expressed across multiple large solid tumor types (NSCLC, CRC, HNSCC, cSCC), offering a broad addressable market.
Dual-masked design is intended to reduce off-target toxicity (cytokine release syndrome) and expand the therapeutic index versus unmasked TCEs.
Combination with pembrolizumab (anti-PD-1) could expand the addressable population if synergy is shown.
Analyst consensus is Strong Buy (12 buy/strong-buy vs 1 hold, 0 sell) with a mean price target of $21, implying ~91% upside from the $11.02 close.
▼ Bear Case5
Still in Phase 1 dose escalation with no efficacy data reported yet, meaning clinical proof-of-concept is years away.
EGFR is a well-established but highly competitive target with multiple approved therapies (EGFR TKIs, cetuximab, etc.) and other bispecific T-cell engagers in development.
As Vir's third TCE program (after VIR-5500 and VIR-5818), it may receive less pipeline priority and resource allocation.
Phase 1 dose-escalation trials in solid tumors have a high attrition rate; T-cell engagers carry cytokine release syndrome risk.
The stock has elevated short-sale volume (58.7% of off-exchange volume on Nov 6, 2026, with a z-score of 2.02 vs its own history), indicating bearish positioning.

Upcoming Catalysts

  • Initial Phase 1 safety and efficacy data from dose escalation (no specific date guided by management)
  • Potential presentation at a future scientific conference (not yet announced)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Vir Biotechnology, Inc. 8-K VIR ·Originating report

Sources · 10

Hover a chip for the title
1 investors.vir.bio2 clinicaltrials.gov3 investors.vir.bio4 businesswire.com5 benzinga.com6 stockanalysis.com7 adisinsight.springer.com8 synapse.patsnap.com9 clinicaltrialsarena.com10 biospace.com